Nyxoah Investor Relations Material
Latest events
Q2 2025
Nyxoah
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nyxoah S.A.
Access all reports
Nyxoah S.A. is a medical technology company that specializes in developing and commercializing innovative treatments for Obstructive Sleep Apnea (OSA). The company's flagship product, the Genio system, offers a patient-centric and CE-Marked hypoglossal neurostimulation therapy designed to treat moderate to severe cases of OSA. This therapy serves as an alternative for patients who are unable or unwilling to tolerate Continuous Positive Airway Pressure (CPAP) treatments. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
NYXH
Country
🇺🇸 United States